GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Gemma Eminowicz, Nicole Concin, Lynda M. McSorley, Vojtech Tlustý, Flora Zagouri, Emad Matanes, Maria Cristina Petrella, Elisabeth Berge Nilsen, Keiichi Fujiwara, Jian 鄄 Liu Wang, Chien‐Hsing Lu, Atthapon Jaishuen
+8 more M. Valeria Cáceres, Sarah Crafton, Destin R. Black, Brian M. Slomovitz, Robert J. Orlowski, Stephan Kruger, Lili Yao, Bradley J. Monk
DOI: 10.1016/j.ijgc.2025.104392
Cited by: 0

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments Cancer Immunotherapy and Biomarkers Ovarian cancer diagnosis and treatment

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
104392–104392
Publication date
1 February 2026
Language
EN